Belite Bio Inc
Research Belite Bio Inc (BLTE) on Bullrun: market cap USD 6.48B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBLTE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.48B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 90.27M
Valuation Snapshot
latest market cap is USD 6.48B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 77.61M | -USD 37.06M | n/a | -2.31 | USD 352.93M | USD 429.00K | USD 770.49M |
| FY2024 | USD 0 | -USD 36.14M | -USD 29.35M | n/a | -1.18 | USD 31.68M | USD 537.00K | USD 145.82M |
| FY2023 | n/a | -USD 31.63M | -USD 29.90M | n/a | -1.19 | USD 88.16M | USD 886.00K | USD 90.43M |
| FY2022 | n/a | -USD 12.65M | -USD 11.85M | n/a | -0.63 | USD 42.09M | USD 866.00K | USD 41.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.48B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.29B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.01B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.26B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 749.75M | n/a | n/a | n/a |
About Belite Bio Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Belite Bio Inc's market cap?
Belite Bio Inc's market capitalization is USD 6.48B.
What does Belite Bio Inc do?
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.